In STEMI, diabetes linked to worse long-term outcomes

January 30, 2013
In STEMI, diabetes linked to worse long-term outcomes
In patients undergoing primary angioplasty for ST-segment elevation myocardial infarction, diabetes is associated with worse long-term outcomes, including mortality, reinfarction, stent thrombosis, and target vessel revascularization, according to research published online Dec. 28 in Diabetes Care.

(HealthDay)—In patients undergoing primary angioplasty for ST-segment elevation myocardial infarction (STEMI), diabetes is associated with worse long-term outcomes, including mortality, reinfarction, stent thrombosis, and target vessel revascularization (TVR), according to research published online Dec. 28 in Diabetes Care.

Giuseppe De Luca, M.D., of the Eastern Piedmont University in Novara, Italy, and colleagues studied the impact of diabetes on long-term outcome in 6,298 patients with STEMI undergoing primary angioplasty with either bare metal stents (BMS) or drug-eluting stents (DES).

Overall, 15.4 percent of patients had diabetes; these patients tended to be older; female; and have hypertension, hypercholesterolemia, and longer ischemia time. At long-term follow-up (1,201 ± 441 days), the researchers found that diabetes correlated with elevated (19.1 versus 7.4 percent); reinfarction (10.4 versus 7.5 percent); stent thrombosis (7.6 versus 4.8 percent), with similar temporal distribution for patients with and without diabetes; and TVR (18.6 versus 15.1 percent). Similar results were seen for patients receiving BMS and DES, except for TVR, for which there was no difference between DES-treated patients with and without diabetes. After adjustment for confounding variables, the impact of diabetes on outcome was confirmed.

"This study shows that, among STEMI patients undergoing primary angioplasty, diabetes is associated with worse long-term mortality, reinfarction, and in-stent thrombosis, even with DES implantation, which was able to overcome the known deleterious effect of diabetes on TVR," the authors write.

Several authors disclosed to the pharmaceutical and medical device industries.

Explore further: Use of newer-generation drug-releasing stent results in lower rate of adverse cardiac events

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Good long-term outcomes for drug-eluting stents

April 4, 2012

(HealthDay) -- Meta-analysis of randomized clinical trials (RCTs) suggests that drug-eluting stents (DESs) significantly reduce repeat revascularizations, with no increase in stent thrombosis (ST), mortality, or recurrent ...

Results of the DEB-AMI Trial reported at TCT 2011

November 10, 2011

A clinical trial that compared the use of drug-eluting balloons (DEB) and bare metal stents (BMS) to both bare metal stents alone and drug-eluting stents (DES) found that the drug-eluting balloon group did not meet the primary ...

Recommended for you

New theory on how insulin resistance, metabolic disease begin

September 26, 2016

Does eating too much sugar cause type 2 diabetes? The answer may not be simple, but a study published Sept. 26 in the Journal of Clinical Investigation adds to growing research linking excessive sugar consumption—specifically ...

Unique molecular atlas of pancreas produced

September 23, 2016

Researchers at Karolinska Institutet have managed to produce the first molecular map of the genes that are active in the various cells of the human pancreas. They have also revealed differences in genetic activity between ...

Can long naps cause diabetes?

September 14, 2016

A study presented at a scientific congress Thursday reported a link between long naps and a higher risk of diabetes, though it couldn't say if daytime sleeping was a symptom or a cause.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.